Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines
- PMID: 7645983
Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines
Abstract
In an effort to enhance the antigenicity of canine tumor cells, canine interferon-gamma (CnIFN-gamma) was applied in vitro to seven canine mammary tumor (CMT) and two canine melanoma (CML) cell lines. Surface expression of major histocompatibility complex (MHC) antigens and tumor-associated antigens (TAA) was measured by a flow cytometric fluorescence assay using commercially available anti-MHC antibodies, and anti-canine TAA monoclonal antibodies generated against CMT and CML cell lines. Compared to constitutive antigen levels in untreated cells, treatment with CnIFN-gamma resulted in increased expression of MHC class I and II antigens (up to 19- and 167-fold, respectively) and a TAA (up to 5-fold) by CMT cell lines, and increased expression of class I antigen (131-fold) by one CML and of class II antigen (18-fold) by the other CML cell line. Expression of MHC antigens and a TAA by tumor cells was increased by Cn-IFN-gamma treatment, and such an increase may be of potential benefit in tumor cell recognition and rejection by the immune system.
Similar articles
-
Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells.Cancer Res. 1990 Dec 1;50(23):7422-9. Cancer Res. 1990. PMID: 1701342
-
An allogeneic hybrid-cell fusion vaccine against canine mammary cancer.Vet Immunol Immunopathol. 2008 Jun 15;123(3-4):289-304. doi: 10.1016/j.vetimm.2008.02.013. Epub 2008 Feb 26. Vet Immunol Immunopathol. 2008. PMID: 18423623 Clinical Trial.
-
Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.Anticancer Res. 1989 Nov-Dec;9(6):1639-47. Anticancer Res. 1989. PMID: 2516715
-
Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma (review).Anticancer Res. 1988 Jan-Feb;8(1):93-5. Anticancer Res. 1988. PMID: 3282476 Review.
-
Biosynthesis and assembly of MHC antigens.Behring Inst Mitt. 1990 Dec;(87):76-9. Behring Inst Mitt. 1990. PMID: 2096822 Review. No abstract available.
Cited by
-
Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.Vaccine. 2007 Nov 1;25(44):7674-86. doi: 10.1016/j.vaccine.2007.08.009. Epub 2007 Aug 24. Vaccine. 2007. PMID: 17913311 Free PMC article.
-
A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs.Vaccine. 2008 Jan 30;26(5):623-38. doi: 10.1016/j.vaccine.2007.11.057. Epub 2007 Dec 17. Vaccine. 2008. PMID: 18180079 Free PMC article.
-
Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.J Vet Intern Med. 2007 Nov-Dec;21(6):1340-6. doi: 10.1892/06-201.1. J Vet Intern Med. 2007. PMID: 18196745 Free PMC article. Clinical Trial.
-
Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma.PLoS One. 2013 Sep 9;8(9):e74897. doi: 10.1371/journal.pone.0074897. eCollection 2013. PLoS One. 2013. PMID: 24040358 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials